NRP1 and nonpapillary renal cell carcinoma: Furthermore, our lab showed that the disruption of the VEGF/NRP1 axis activates proangiogenic and protumorigenic signaling in endothelial and tumor cells via Tumor targeting peptides (TTP); liposomes encapsulating both everolimus (a small molecule inhibitor) demonstrated tumor growth retardation in ccRCC models, improving overall therapeutic outcome in ccRCC patients [78].